3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 4
1
Phase 3
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
9
Gastrointestinal
6
Thoracic
2
Other solid neoplasm
2
Genitourinary
2
CNS
2
Sarcoma
1
Gynecologic
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
102
Radiotherapy
47
Bevacizumab
33
Carboplatin
23
Irinotecan
20
pembrolizumab
17
Radiosurgery
16
Nivolumab
16
Radiation
14
Cyclophosphamide
11
Magnetic Resonance Spectroscopy
10
fludarabine
8
Trastuzumab
8
Radiotherapy, Intensity-Modulated
8
Carmustine
8
Surgical Procedures, Operative
7
Specimen Handling
7
Pemetrexed
7
Paclitaxel
7
Interleukin-2
7
Filgrastim
7
Everolimus
7
Erlotinib Hydrochloride
7
temsirolimus
6
Vorinostat
6
Radiotherapy, Conformal
6
Lomustine
6
Ipilimumab
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Gemcitabine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
trastuzumab deruxtecan
×
CNS
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled